At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Danvatirsen, and 6 other interventions for Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 528 participants across 45 sites in 8 countries.
Detailed Summary
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Study Details
Timeline
Interventions
Participants will receive IV infusion of durvalumab as stated in arm description.
Participants will receive IV infusion of danvatirsen as stated in arm description.
Participants will receive oral tablet of ceralasertib as stated in arm description.
Participants will receive oral tablets of vistusertib as stated in arm description.
Participants will receive oral tablets of olaparib as stated in arm description.
Participants will receive IV infusion of oleclumab as stated in arm description.
Participants will receive IV infusion of trastuzumab deruxtecan as stated in arm description.
Participants will receive oral tablets of cediranib as stated in arm description.